Absence of methicillin-resistant Staphylococcus aureus colonization among immunocompetent healthy adults: Insights from a longitudinal study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 10 09 2020
accepted: 12 06 2021
entrez: 30 6 2021
pubmed: 1 7 2021
medline: 19 11 2021
Statut: epublish

Résumé

Methicillin-resistant Staphylococcus aureus (MRSA) has long been known as a major cause of hospital-acquired (HA-MRSA) infections worldwide. For the past twenty years, an increasing number of studies have described its emergence in the community as well. In Portugal, a country with a high-prevalence of HA-MRSA, there are only limited data available on the epidemiology of MRSA in the community. We studied the prevalence of S. aureus and MRSA colonization among healthy adults in Portugal. Between February 2015 and December 2016, a longitudinal study was conducted in which 87 adults aged 25-50 years old were followed for six months. For each participant nasopharyngeal, oropharyngeal and saliva samples were obtained monthly and, in some cases, weekly. A total of 1,578 samples (n = 526 for each sampling site) were examined for the presence of S. aureus and MRSA by classical culture-based methods. Fifty-seven adults (65.5%) carried S. aureus at least once during the six months period of the study: 19.5% were persistent S. aureus carriers and 46.0% were intermittent carriers. Carriage rates per sampling site were 20.5% in nasopharynx, 18.3% in oropharynx, and 13.5% in saliva. Simultaneous screening of the three sampling sites increased detection of S. aureus, which overall occurred in 34.4% of the 526 sampling time-points. No MRSA were isolated. In conclusion, this study adds novel information about the MRSA scenario in the Portuguese community. Our results indicate that, in Portugal, MRSA does not seem to circulate among healthy adults without risk factors and therefore this age group does not constitute, at the current time, a reservoir of MRSA in the community.

Identifiants

pubmed: 34191834
doi: 10.1371/journal.pone.0253739
pii: PONE-D-20-28570
pmc: PMC8244897
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0253739

Déclaration de conflit d'intérêts

This work was partially supported by an Investigator-Initiated Research Grant from Pfizer to RSL. Other authors declare no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Microb Drug Resist. 2001 Fall;7(3):237-45
pubmed: 11759085
PLoS One. 2019 Feb 8;14(2):e0212052
pubmed: 30735539
Curr Top Microbiol Immunol. 2016;398:55-87
pubmed: 27370344
JAMA. 1999 Sep 22-29;282(12):1123-5
pubmed: 10501104
N Engl J Med. 1998 Aug 20;339(8):520-32
pubmed: 9709046
J Clin Microbiol. 2008 Sep;46(9):2912-7
pubmed: 18614664
Ann Clin Microbiol Antimicrob. 2018 May 4;17(1):18
pubmed: 29728115
J Hosp Infect. 2017 Jul;96(3):232-237
pubmed: 28246002
Lancet Infect Dis. 2005 Dec;5(12):751-62
pubmed: 16310147
J Clin Microbiol. 2006 Sep;44(9):3334-9
pubmed: 16954269
New Microbes New Infect. 2015 Dec 01;9:24-34
pubmed: 26862431
BMC Infect Dis. 2010 May 03;10:110
pubmed: 20438633
J Antimicrob Chemother. 2012 Jun;67(6):1325-32
pubmed: 22378682
Eur J Clin Microbiol Infect Dis. 2015 Mar;34(3):593-600
pubmed: 25359581
BMC Infect Dis. 2014 Dec 31;14:723
pubmed: 25551464
Clin Microbiol Infect. 2009 Feb;15(2):149-55
pubmed: 19154489
J Hosp Infect. 1993 Oct;25(2):97-108
pubmed: 7903093
Epidemiol Infect. 2010 May;138(5):673-6
pubmed: 20144250
Emerg Infect Dis. 2001 Mar-Apr;7(2):178-82
pubmed: 11294701
Int J Med Microbiol. 2017 Jan;307(1):21-27
pubmed: 28017539
Euro Surveill. 2008 Oct 02;13(40):
pubmed: 18831950
J Epidemiol Glob Health. 2013 Sep;3(3):165-73
pubmed: 23932059
Medicine (Baltimore). 2019 May;98(18):e15499
pubmed: 31045837
Microb Drug Resist. 2013 Dec;19(6):483-90
pubmed: 24171450
Clin Microbiol Rev. 2010 Jul;23(3):616-87
pubmed: 20610826
J Antimicrob Chemother. 2017 May 1;72(5):1285-1288
pubmed: 28108681
Int J Med Microbiol. 2018 Jun;308(4):469-475
pubmed: 29661650
J Infect Dis. 2021 May 20;223(9):1590-1600
pubmed: 32877517
Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1521-1529
pubmed: 29948361

Auteurs

Sónia T Almeida (ST)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

A Cristina Paulo (AC)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

João Babo (J)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

João Borralho (J)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Catarina Figueiredo (C)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Bruno Gonçalves (B)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

João Lança (J)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Mónica Louro (M)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Hermes Morais (H)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Joana Queiroz (J)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Hermínia de Lencastre (H)

Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.
Laboratory of Microbiology and Infectious Diseases, The Rockefeller University, New York, NY, United States of America.

Raquel Sá-Leão (R)

Laboratory of Molecular Microbiology of Human Pathogens, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH